Hilo Raises $42M to Scale AI-Driven Blood Pressure Monitoring
Hilo, previously known as Aktiia, has raised $42 million in an oversubscribed Series B round co-led by Earlybird Health and Wellington Partners.The company has now surpassed $100 million in total funding to support its vision of AI-powered, cuffless blood pressure monitoring at scale.
At the core of Hilo’s platform is a foundation machine learning model built from billions of optical signals collected from real-world users.
This model, trained on hundreds of millions of calibration points, allows for precise, continuous monitoring without the need for traditional cuffs.
Also read:
Turning Data Into Health Insights
Hilo’s AI doesn’t just track—it interprets. The system analyzes optical signals from wearable sensors and provides meaningful, clinically validated reports.
Its smart algorithms transform raw data into actionable insights for both individuals and healthcare professionals.
With approvals secured in Canada, Australia, and Saudi Arabia, and CE marking already in place, Hilo is now eyeing US FDA clearance. The company’s AI capabilities have driven 76% annual revenue growth and underpinned clinical trials now submitted for regulatory review.
A Platform Built for Global Impact
The rebrand to Hilo reflects a broader mission: making AI-enabled hypertension management both universal and intuitive. According to Earlybird’s Christoph Massner, Hilo bridges “clinical reliability and everyday usability” through intelligent technology and a seamless user experience.
Wellington Partners’ Johannes Fischer said AI-led access to real-time data could transform care for one of the world’s top health risks. Headquartered in Switzerland, Hilo is applying advanced AI to redefine blood pressure monitoring and turning personalized health insights into a daily reality.
